New Study Reveals Extensive Pancreatic Nerve Damage in Cystic Fibrosis, Offering New Clues to Cystic Fibrosis-Related Diabetes

Dr. Larson Ode
Dr. Norris

A study from our Division has uncovered a previously unrecognized consequence of cystic fibrosis (CF): extensive damage to the nerves within the pancreas. The findings suggest that loss of these nerve connections may contribute to the hormone abnormalities that place many individuals with CF at risk for developing cystic fibrosis-related diabetes (CFRD).

The pancreas depends on signals from the nervous system to coordinate the release of hormones that regulate blood sugar and digestion. By examining pancreatic tissue, the investigators found that the nerve content was dramatically reduced and altered when CF was present. Notably, many of the hormone-producing cells of the pancreas remained present and retained the capacity to function, suggesting that disrupted nerve signaling may play an important role in pancreatic hormonal dysfunction in CF. Encouragingly, when early pancreatic injury was prevented through treatment with a CFTR modulator, nerve connections were preserved and hormone responses improved. These findings indicate that some endocrine abnormalities in CF may result not only from damage to hormone-producing cells, but also from disruption of the nerve connections that help regulate their activity.

This research provides important new insight into how CF affects the pancreas and offers a potential new framework for understanding the development of CFRD and other metabolic complications of the disease. The findings have been published in the journal Clinical Science. Division personnel who contributed to the study included Shanming Hu, Dr. Larson Ode, and Dr. Norris who served as the study’s senior author. The study abstract is available on PubMed at this link.

Patient Choice Award Recipients – 2026

We are pleased to report that 3 of the pediatric endocrinology providers in our division have received Patient Choice Awards. These awards are given out by UI Health Care to recognize physicians for consistently providing patients with an excellent healthcare experience with ratings in the top 10% nationally. The recipient physicians were:

Dr. Kanner receiving a Patient’s Choice Award.
  • Lauren Kanner, MD
  • Liuska Pesce, MD
  • Akhila Ramakrishna, MD

Notably, Dr. Pesce has received the award for 6 consecutive years!!

The Choice Award was earned by only 310 outpatient providers across the entire institution. The Award recognizes those who scored in the top 10% nationally in response to patient surveys asking whether the physician showed concern for patient questions or worries, gave explanations about problem or condition, made efforts to include the patient in care decisions, discussed proposed treatments (options, risks, benefits, etc), and whether they would be likely to recommend the care provider to others. Our division is fortunate to have these Award winning physicians on our team. We thank each of them for their wonderful work.

Our Program Ranked Among the Best Children’s Diabetes & Endocrinology Programs Nationally

We are excited to share that our Division has been rated among the Best Children’s Hospitals for Diabetes & Endocrinology Care by the US News 2026-2027 annual national report, where we were ranked #33 nationwide. Other top ranked specialties at the University of Iowa Stead Family Children’s Hospital included neonatology, nephrology, neurology, cardiology, urology, and behavioral health.

“Our ongoing year-on-year national ranking is a testament to the unwavering dedication and expertise of our pediatric endocrine physicians, advanced practice providers, specialty nurses, diabetes educators, psychologists, researchers, medical assistants, dieticians, pharmacists, social workers, and all teams members. We remain devoted to provide the best endocrine and diabetes care for the children and adolescents in the region and beyond.”

Andrew Norris, M.D. Ph.D.
Director, Division of Endocrinology and Diabetes
UI Stead Family Children’s Hospital

New Publication Highlights Links Between CFTR Function, Pancreatic Health, and Cancer Risk

Dr. Norris

A new study demonstrates that CFTR function can slow pancreatic ductal-cell growth while beneficially reshaping key pathways that regulate cell proliferation. The findings are especially relevant to endocrinology given the close, but still incompletely understood, relationship between pancreatic disease, diabetes, and pancreatic cancer. As highly effective CFTR modulators continue to transform care for people with cystic fibrosis, this work provides new insight into how these therapies may influence long-term pancreatic health and disease risk. Dr. Norris from our Division contributed to the publication, which can be found at this pubmed link.

Progress Understanding Glycogen Storage Disease (Type III)

Dr. Larson Ode

Hypoglycemia is a frequent manifestation of glycogen storage diseases. As such, pediatric endocrinologists are often aid in the diagnosis and/or treatment of these diseases. To this end, Dr. Larson Ode has been assisting a new team of scientists who are working to better understand how to manage glycogen storage diseases. In a new scientific article, this group has characterized the genetic, metabolic, and lipidomic profiles of cultured fibroblasts from nine different persons affected by glycogen storage disease type III. These now well-characterized cell lines will be a useful tool to test new therapeutic approaches. The work is published in the journal Molecular Genetics and Metabolism, and its abstract can be found on PubMed at this link.

Dr. Power in the Spotlight

Dr. Power

Our current third-year fellow, Dr. Greg Power, was recently highlighted in the Fellow Spotlight section of the Pediatric Endocrine Society’s July 2026 newsletter. The feature on Dr. Power can be found at this link. In the article, Dr. Power discusses his Iowa roots and his medical education journey. We are grateful that he chose Pediatric Endocrinology as his field and that he is completing his fellowship training in our division.

The Pediatric Endocrine Society has more than 1,600 members dedicated to the care of children with endocrine disorders. The Society advances education, research, and clinical care while also supporting the training and development of future pediatric endocrinologists, such as Dr. Power. We were thrilled to see Dr. Power recognized in this month’s Fellow Spotlight and proud to have him represent our division.

Division Faculty Member Co-Authors Landmark Study Showing New Hope for Patients with Acquired Hypothalamic Obesity

Dr. Larson Ode

We are proud to recognize Dr. Larson Ode as a co-author of a groundbreaking clinical trial published last week in the New England Journal of Medicine. The study demonstrates the effectiveness of a novel treatment of acquired hypothalamic obesity, a rare and devastating condition that until now has lacked effective medical therapies. In the phase 3 trial, researchers evaluated setmelanotide in children and adults with hypothalamic obesity resulting from tumors, injuries, or other damage to the hypothalamic region of the brain. After 52 weeks of treatment, participants receiving setmelanotide experienced a 16.5% reduction in body mass index (BMI) on average, while those receiving placebo showed an increase in BMI. The findings represent an important breakthrough for patients and families affected by hypothalamic obesity, a condition that is notoriously difficult to treat because it disrupts the brain pathways that regulate appetite and energy balance. By targeting the key brain pathways involved, setmelanotide addresses the mechanisms underlying the disease rather than simply treating its symptoms. Published in one of the world’s leading medical journals, this study provides compelling evidence that setmelanotide may offer a much-needed therapeutic option for individuals living with acquired hypothalamic obesity. We congratulate Dr. Larson Ode and her co-authors on this significant achievement and on their contributions to advance care for patients with complex obesity disorders. The study’s abstract can be found at this PubMed link.

Dr. Larson Ode also contributed to a followup article published shortly after the above main article. The followup article describes the impact of setmelanotide on the participants’ energy levels, physical activity, and their perception of the impact of the medication on their quality of life. This very practical outcome measure is extremely important, arguably even more than the biological outcomes addressed in the original article. The reason is that hypothalamic obesity is associated with poor energy levels and substantial reductions in quality of life, beyond simple obesity. This study found meaningful improvements in perceived energy and activity levels in the majority of participants receiving setmelanotide but only in a very small fraction of those receiving placebo. It is important that this new therapy has the potential to improve quality of life in people who have acquired hypothalamic obesity. The study’s abstract can be found at this PubMed link.

Announcing New Pediatric Endocrine Fellow: Dr. Gu

Dr. Gu

Today we are thrilled to announce that Dr. Amy Gu has joined our division as a new pediatric endocrine fellow. She will serve three years in this role, after which she will be a full-fledged, board-eligible pediatric endocrinologist. Dr. Gu received her Medical Doctorate degree from the University of Missouri-Kansas City School of Medicine where she was enrolled in their accelerated program. She just completed a three-year pediatric residency at the University of Iowa. As an undergraduate medical student, she received the Sarah Morrison Research Grant Award. She has volunteered at Diabetes Camp Hertko Hollow. In 2025, she was selected to join the PedsENDO Discovery Program administered by the Pediatric Endocrine Society. With these experiences, we are thrilled to give a warm welcome from all of us to Dr. Gu!!

Dr. Norris Contributes to Major New Reference in Diabetes Research and Care

Dr. Norris

We are pleased to recognize Dr. Norris for co-authoring a chapter in the newly published textbook Modern Diabetology: Basic Science and Clinical Practice. This authoritative volume brings together internationally recognized experts to provide a comprehensive overview of the latest advances in diabetes research, translational science, and clinical management. Designed as a practical resource for physicians and researchers alike, the textbook addresses the rapidly evolving landscape of diabetes care while highlighting important scientific discoveries and evidence-based clinical practices. Dr. Norris co-authored Chapter 18, “Cystic Fibrosis–Related Diabetes,” an increasingly important topic at the intersection of endocrinology and cystic fibrosis care. As survival continues to improve for individuals with cystic fibrosis, the recognition and management of cystic fibrosis–related diabetes have become critical to optimizing long-term health outcomes and quality of life. We congratulate Dr. Norris on his contribution to this publication and thank him for sharing his expertise to help advance the understanding and care of patients living with diabetes and related endocrine disorders.

Dr. Baum Completes Pediatric Endocrine Fellowship

Dr. Kyle Baum

We are extremely proud of Dr. Kyle Baum. For the past 3 years, Dr. Baum has been a pediatric endocrinology fellow in our program. Today he finishes this training and will officially become a “board eligible” pediatric endocrinologist. During these past three years, Dr. Baum has been an exemplary fellow, delivering excellent clinical care and demonstrating exceptional clinical interpersonal skills and judgement. He has become known for his unique knock before entering a patient room and for fist bumping all his patients who participate in crafting their health care plan. His contributions include being an enthusiastic volunteer at Diabetes Camp Hertko Hollow. While a fellow, he has been an energetic scholar, creating two very different studies to examine how modern weight-loss medications, such as GLP1RAs, impact skeletal muscle health. One of these studies, involving a model system, is nearly complete – look for a future publication. The other study will occur as a future clinical research project. Dr. Baum will be taking an academic position as a Pediatric Endocrinology attending in the Sanford Health system. Congratulations Dr. Baum on completing fellowship!!!